|
|
 |
|
Viewing report
|
|
|
|
State of the Pharmaceutical Industry, 2008
Decision Resources, Inc., Jan 2008, Pages: 43
Executive Summary
- Strategic Considerations
- Trends and Their Implications for Stakeholders
2008: Charting New Waters
The Haves and the Have-Nots: Propelling Companies Toward Novel Options
- Predicting a Growing Divide
- Surviving Fallow Periods Will Become More Difficult
- Superimposing the Generic Dimension Widens the Have/Have-Not Divide
- Coping Strategies Will Force New Business Models
Personalized Information: Who Will Provide It?
- Recent Trends in Communicating Information on Drugs and Health Care
- Providing Unbiased Drug Information
- The Value of Social Networking
- Educating Physicians: Evidence-Based Medicine and Counter-Detailing
Globalization: Threat or Opportunity
- Expanding into Emerging Pharmaceutical Markets
- Different Pharmaceutical Markets Developing in China and India
- No Longer Simply a Matter of Cost
- Moving Upstream in the R&D Value Chain
- Japan’s Evolving Pharmaceutical Marketplace
- Growing Impact of Foreign Pharmaceutical Companies
- Domestic Japanese Companies: To Merge or Not to Merge?
- Striving to Stay Independent
Pharma Pricing 2008: Make or Break
- Crumbling Industry Defenses
- Emboldened Customer Offensives
Technology Assessment: The Case of Alzheimer’s Drugs
- Technology Assessments
- The Case of Alzheimer’s Drugs
- Actions Going Forward
Convergence: Are We There Yet?
- Targeted Therapies
- Biomarker-Driven Personalized Medicine: The Way Forward in Cancer Therapy
- An Analysis of Industry Trends in Personalized Medicine
- Trends Identified by the Diaceutics Google Index
- Lack of an Appropriate Business Model
- Convergence
Industry Action Items Going Forward
Experts Featured:
- John Ansell, M.A., principal, John Ansell Consultancy
- Cheryl Barton, Ph.D., principal
- R. Roman Boutellier, Ph.D., Swiss Federal Institute of Technology, Zurich
- Caroline Fielding, deputy managing director, Virgo Health PR
- Sarah W. Fuller, president, Decision Resources, Inc.
- Jeffrey Gruen, M.D., M.B.A., chief medical officer, Revolution Health
- Barrie G. James, Ph.D., principal, Pharma Strategy Consulting
- James McDermott, vice president, consulting, Decision Resources, Inc.
- Mollie Roth, J.D., corporate counsel, vice president of business development, Diaceutics
- Alexander J. Schicker, M.Sc., Swiss Federal Institute of Technology, Zurich
- Jeffrey Settleman, Ph.D., professor of medicine at Harvard Medical School and director,
- Center for Molecular Therapeutics at the Massachusetts General Hospital Cancer Center
- Hiroshi Tashiro, M.Sc., research manager of Decision Resources’ Tokyo office
- Fredrik Ullman, M.Sc., Swiss Federal Institute of Technology, Zurich
- Prachi Vora, M.P.H., Spectrum program manager, Decision Resources, Inc.
Tables:
1. Number of Phase III NCEs in Development by the Top Five Pharmaceutical Companies, 2007
2. Top Five Pharmaceutical Companies: Impact of Patent Expiry Versus Number of Phase III NCEs in Development
3. Globalization of Biotechnology, 2006
4. Foreign Multinational Players: Select Japanese Market Strategies and Equity Transfers, 2002-2007
5. Mergers and Acquisitions of Key Japanese Pharmaceutical Companies, 2002-2007
6. Spectrum Scorecard: Pharma Action Items Going Forward, 2008
Figures:
1. 2008’s Pharmaceutical Industry: Wrestling with New Options
2. Number of Products Achieving Global Sales Thresholds, 2006
3. Mature and Emerging Pharmaceutical Markets, 2007
4. Globalization: Rapidly Developing Asian Pharmaceutical Markets
5. China and India: Pharmaceutical Market Comparison
6. Number of Drugs Launched in the Japanese Market by Major Companies, 2002-2006
7. Tyrosine Kinases and Their Targeted Therapies
8. Diaceutics Google Index (DGi) for Personalized Medicine, June 2005-June 2007
9. Diaceutics Google Index (DGi) for Personalized Medicine Topics
Also available
State of the Pharmaceutical Industry, 2007
Customers who bought this item also bought
Personalized Medicine - Scientific and Commercial Aspects
Dealmaking and Business Strategies in the Age of Personalized Medicine
Personalized Medicine
Companion Diagnostics in Personalized Medicine and Cancer Therapy
How to Integrate Personalized Medicine into Business Strategies
Beyond The Blockbuster Drug: Strategies For Nichebuster Drugs, Targeted Therapies and Personalized Medicine.
Fulfilling the Promise of Personalized Medicine Through Next-Generation Sequencing
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Personalized Medicine: The Impact of Pharmacogenomics on Pharmaceutical R&D and Sales
Cancer Personalized Medicine 2008
The Trend Toward Personalized Medicine
Nucleic Acid Testing: A Vehicle for Advancing Personalized Medicine
|
|
|
|
